मलेशिया - अंग्रेज़ी - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

synerrv sdn bhd - desloratadine -

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

bayer new zealand limited - desloratadine 5mg - film coated tablet - 5 mg - active: desloratadine 5mg excipient: calcium hydrogen phosphate dihydrate carnauba wax maize starch opadry blue 32b10817 opadry clear ys-1-19025-a powdered cellulose purified talc white beeswax

जॉर्डन - अंग्रेज़ी - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

مستودع أدوية أداتكو - adatco drug store - desloratadine 5 mg - 5 mg

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

rebel distributors corp - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r) - desloratadine 5 mg - clarinex is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. clarinex is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. clarinex is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older. clarinex tablets 5 mg are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients, or to loratadine. there is no information to indicate that abuse or dependency occurs with clarinex tablets.

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

merck sharp & dohme corp. - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r) - desloratadine 5 mg - clarinex® is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. clarinex is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. clarinex is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older. clarinex tablets, reditabs, and oral solution are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see warnings and precautions (5.1) and adverse reactions (6.2)]. risk summary the limited available data with clarinex in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. there are no adequate and well-controlled studies in pregnant women. desloratadine given during organogenesis to pregnant rats was not teratogenic at the

फ़िलिपींस - अंग्रेज़ी - FDA (Food And Drug Administration)

merck sharp & dohme (i.a.) llc - desloratadine - tablet - 5 mg

बेल्जियम - अंग्रेज़ी - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

eg sa-nv - desloratadine 0,5 mg/ml - oral solution - 0,5 mg/ml - desloratadine 0.5 mg/ml - desloratadine

बेल्जियम - अंग्रेज़ी - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - desloratadine 2,5 mg - orodispersible tablet - 2,5 mg - desloratadine 2.5 mg - desloratadine

बेल्जियम - अंग्रेज़ी - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

teva pharma belgium sa-nv - desloratadine 0,5 mg/ml - oral solution - 0,5 mg/ml - desloratadine 0.5 mg/ml - desloratadine

संयुक्त राज्य - अंग्रेज़ी - NLM (National Library of Medicine)

bryant ranch prepack - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r) - desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older. desloratadine tablets are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 12 years of age and older. desloratadine tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see warnings and precautions (5.1) and adverse reactions (6.2)]. risk summary   the limited available data with desloratadine in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. there are no adequate and well-controlled studies in pregnant women. desloratadine given during organogenesis to pregnant rats was not teratogenic at the summed area under the concentration-time curve (auc)-based exposures of desloratadine and its metabolite approximately 320 times that at the recommended human daily oral dose (r